Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Common Equity (2019 - 2025)

Cellebrite DI's Common Equity history spans 7 years, with the latest figure at $484.3 million for Q4 2025.

  • Quarterly Common Equity rose 44.13% to $484.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $484.3 million through Dec 2025, up 44.13% year-over-year, with the annual reading at $484.3 million for FY2025, 44.13% up from the prior year.
  • Common Equity came in at $484.3 million for Q4 2025, up from $336.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $484.3 million in Q4 2025 to a low of -$130.0 million in Q3 2021.
  • The 5-year median for Common Equity is $46.8 million (2022), against an average of $101.1 million.
  • Year-over-year, Common Equity tumbled 214.96% in 2021 and then skyrocketed 882.17% in 2024.
  • Cellebrite DI's Common Equity stood at -$73.3 million in 2021, then soared by 200.71% to $73.9 million in 2022, then plummeted by 53.68% to $34.2 million in 2023, then surged by 882.17% to $336.0 million in 2024, then surged by 44.13% to $484.3 million in 2025.
  • Per Business Quant, the three most recent readings for CLBT's Common Equity are $484.3 million (Q4 2025), $336.0 million (Q4 2024), and $34.2 million (Q4 2023).